A first-in-human, phase 1 study evaluating oral TACC3 inhibitor, AO-252, in advanced solid tumors.

被引：0
|
作者：
Dumbrava, Ecaterina Elena
Kennon, Amber Michelle
Balema, Wintana A.
Lim, Chaemin
Vempati, Sridhar
Stergiopoulos, Sotirios
Richardson, Debra L.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA
[2] A2A Pharmaceut Inc, New York, NY USA
[3] Univ Oklahoma, Div Gynecol Oncol, Stephenson Canc Ctr, Hlth Sci Ctr, Oklahoma City, OK USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3176
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase 1, first-in-human study of IK-930, an oral TEAD inhibitor targeting the Hippo pathway in subjects with advanced solid tumors
    Tolcher, Anthony W.
    Lakhani, Nehal J.
    McKean, Meredith
    Lingaraj, Trupti
    Victor, Laura
    Sanchez-Martin, Marta
    Kacena, Katherine
    Malek, Karim S.
    Santillana, Sergio
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] A first-in-human phase I study of ER-α36 modifier icaritin in patients with advanced solid tumors.
    Fan, Ying
    Xu, Binghe
    Ding, Xiaoyan
    Ma, Fei
    Wang, Jiayu
    Yuan, Peng
    Luo, Yang
    Li, Qing
    Zhang, Pin
    Cai, Ruigang
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] A first-in-human phase 1 dose escalation study of FF-10850 (liposomal topotecan) in patients with advanced solid tumors.
    Matulonis, Ursula A.
    Janku, Filip
    Moser, Justin C.
    Fu, Siqing
    Wages, David S.
    Wheeler, Catherine A.
    Mori, Mikinaga
    Shimoyama, Susumu
    Yamada, Naoki
    Subach, Ruth Ann
    Cheung, Kin
    Madden, Timothy
    Maier, Gary
    Johansen, Mary
    Falchook, Gerald Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [34] A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors.
    Burris, Howard A., III
    Spira, Alexander I.
    Taylor, Matthew H.
    Yeku, Oladapo O.
    Liu, Joyce F.
    Munster, Pamela N.
    Hamilton, Erika P.
    Thomas, Jacob Stephen
    Gatlin, Frances
    Penson, Richard T.
    Abrams, Thomas Adam
    Dhawan, Mallika Sachdev
    Walling, Jacqueline M.
    Frye, John W.
    Romanko, Kevin
    Sung, Victoria
    Brachmann, Carrie
    El-Khoueiry, Anthony B.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] First-in-human (FIH) phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors.
    Xu, Jian-Ming
    Wang, Yan
    Chen, Yu-ling
    Jia, Ru
    Shen, Lin
    Wang, Jian
    Sai, Yang
    Qi, Chuan
    Mu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] First-in-human phase I study of JPH203, L-type amino acids transporter 1 inhibitor, in patients with advanced solid tumors.
    Okano, Naohiro
    Kawai, Kirio
    Kobayashi, Takaaki
    Nagashima, Fumio
    Endou, Hitoshi
    Furuse, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors.
    Schwartz, Gary K.
    Adkins, Douglas
    Heist, Rebecca Suk
    Abbott, Maura
    Barber, Stephanie L.
    Chao, Richard C.
    Neuteboom, Saskia T. C.
    Chen, Isan
    Christensen, James
    Bauer, Todd Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] First-in-human Phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors.
    Hollebecque, Antoine
    Soria, Jean-Charles
    Bahleda, Ratislav
    Lopez-Busto, Natividad
    Jacquet-Bescond, Anne
    Burbridge, Mike F.
    Valerie, Cattan
    Pauly, Jeanne
    Herranz, Maria
    Azaro, Analia
    Depil, Stephane
    Rodon, Jordi
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [39] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Infante, Jeffrey R.
    Mendelson, David S.
    Burris, Howard A., III
    Bendell, Johanna C.
    Tolcher, Anthony W.
    Gordon, Michael S.
    Gillenwater, Heidi H.
    Arastu-Kapur, Shirin
    Wong, Hansen L.
    Papadopoulos, Kyriakos P.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (02) : 216 - 224
  • [40] First-in-human study of AMG 208, an oral MET inhibitor, in adult patients (pts) with advanced solid tumors
    Hong, David S.
    Rosen, Peter J.
    Lockhart, A. Craig
    Fu, Siqing
    Janku, Filip
    Kurzrock, Razelle
    Khan, Rabia
    Amore, Benny
    Caudillo, Isaac
    Deng, Hongjie
    Hwang, Yuying C.
    Loberg, Robert D.
    Shubhakar, Poornima
    Zoog, Stephen
    Beaupre, Darrin M.
    Lee, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345